The prospect of establishing a specially focused orphan drug megafund, through which investors put money down and collect on the spoils as drugs and intellectual property rights are sold to venture capitalists or pharma firms, is one due to be explored during a panel talk at the Allicense 2015 conference by Andrew Lo, Sloan professor of finance at the Massachusetts Institute of Technology (MIT).